SynthesisJournal of translational medicine2025
Unlocking the potential of stem cell-derived extracellular vesicles in osteoporosis therapy: a systematic review and meta-analysis of preclinical studies.
Synthesis in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveIn recent years, stem cell-derived extracellular vesicles (SC-EVs) have garnered widespread attention for the treatment of osteoporosis. Based on all available data, we conducted a comprehensive evaluation of the efficacy of SC-EVs in preclinical studies, aiming to provide the latest evidence to support their clinical translation.
methodsA comprehensive search was conducted in PubMed, Cochrane, Embase, and Web of Science databases for preclinical studies on SC-EVs for the treatment of osteoporosis, with the search period ending on November 10, 2024. Data extraction focused on three main aspects: general bone analysis parameters, histological quantification, and serum bone turnover markers. Additionally, the reporting quality and risk of bias of the studies were rigorously assessed.
resultsA total of 21 studies met the inclusion criteria and were included in the final meta-analysis. The results showed that SC-EVs treatment, compared to placebo, significantly increased bone mineral density, bone volume fraction, trabecular number, and trabecular thickness, while reducing trabecular separation. Furthermore, SC-EVs treatment promoted an increase in osteoblast numbers, inhibited osteoclast numbers, and enhanced bone mineralization. Despite the presence of heterogeneity and publication bias, the results were relatively robust.
conclusionsCompared with placebo, SC-EV treatment increased bone mass and strength, improved bone microarchitecture, and enhanced biomechanical properties. These effects may be associated with the regulation of bone homeostasis through osteoblasts and osteoclasts within trabecular bone. In summary, SC-EVs demonstrate great potential in regulating bone homeostasis in osteoporosis. However, rigorous and standardized quality control in future studies is essential to facilitate the clinical translation of SC-EVs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.